Long-term suppression of neuropeptide Y after pulmonary vein ablation promotes cardiomyocyte apoptosis and fibroblast activation, potentially driving atrial fibrillation recurrence.
NPY downregulated post-ablationMulti-omics profiling identified neuropeptide Y as a key protein suppressed after cardiac ablation, with its loss promoting both cell death and fibrosis that drive arrhythmia recurrence
What the researchers found
Multi-omics profiling identified NPY as significantly downregulated after pulmonary vein ablation. NPY suppression promoted cardiomyocyte apoptosis and activated the Akt pathway in cardiac fibroblasts, increasing fibrosis. NPY intervention alleviated atrial myocyte apoptosis and inhibited Akt activation in fibroblasts. The atrial effective refractory period was shortened after ablation.
Why it matters
Atrial fibrillation affects millions worldwide and catheter ablation is a primary treatment, yet recurrence rates remain frustratingly high. Understanding that NPY suppression after ablation actively promotes the conditions for recurrence opens a potential therapeutic avenue — supplementing NPY could help prevent AF from coming back.
The numbers in context
The study used transcriptome and proteome profiling via high-throughput sequencing and TMT-tagged LC-MS analysis in a long-term canine model.
How the study worked
Animal study using a long-term beagle dog model after circumferential pulmonary vein ablation (CPVA). Transcriptome profiling via high-throughput sequencing and proteome analysis via TMT-tagged LC-MS. Differentially expressed genes and proteins were identified, with NPY selected for functional validation in cell experiments and tissue analysis.
Who was studied
Beagle dogs after circumferential pulmonary vein ablation
What this study cannot tell us
Canine model may not fully replicate human cardiac physiology after ablation. The number of dogs used was not specified. The molecular pathway (NPY → apoptosis/fibrosis → AF reinduction) is proposed but the causal chain needs further validation. Translating NPY supplementation to human therapy faces significant pharmacological challenges.
How to read the evidence
Preliminary evidence from an animal study using sophisticated multi-omics methodology. The mechanistic findings are compelling but require validation in human tissue and clinical studies.
When this study was published
Published in 2024, offering a novel mechanistic perspective on post-ablation AF recurrence.
The bigger picture
This study connects neuropeptide signaling to cardiac arrhythmia in a new way. While NPY is best known for its roles in appetite and stress, its cardiac protective effects could represent a new therapeutic target for preventing AF recurrence — a major unmet need in cardiology.
Questions still open
- Could NPY supplementation or Y-receptor agonists be given after catheter ablation to reduce atrial fibrillation recurrence?
- Is NPY suppression also seen in human cardiac tissue after ablation procedures?
- Would restoring NPY levels be sufficient to prevent fibrosis, or are other pathways also involved?
Common questions
What is catheter ablation and why does AF come back?
How could neuropeptide Y help prevent AF recurrence?
Read the original research
Multiomics analysis of canine myocardium after circumferential pulmonary vein ablation: Effect of neuropeptide Y on long-term reinduction of atrial fibrillation.
Journal of cellular and molecular medicine, 28(15), e18582
Citation
Song, Qiyuan; Zhang, Ning; Zhang, Yujiao; Zhang, An; Li, Huilin; Bai, Shuting; Shang, Luxiang; Du, Juanjuan; Hou, Yinglong. (2024). Multiomics analysis of canine myocardium after circumferential pulmonary vein ablation: Effect of neuropeptide Y on long-term reinduction of atrial fibrillation.. Journal of cellular and molecular medicine, 28(15), e18582. https://doi.org/10.1111/jcmm.18582